Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

3rd Annual Stability Testing Conference

Next-Gen Sequencing Trends 2009

Competitor Analysis: c-MET/HGF Inhibitors

The Japanese Pharmaceutical Market 2008-2023

New Products

Japanese Pharmaceutical Market 2009-2024

3rd Annual Lyophilisation Conference

The Global Bioinformatics Market: Market size, forecasts and company profiles

Pharmaceutical Mergers and Acquisitions (PH133)

Pharmaceutical Speaker Programs (PH134) Measuring ROI and Communicating Value

Strategic Clinical Sourcing (PH125)) Managing Costs and CROs

The Global Analgesics Market 2009-2024

Competitor Analysis: Coagulation Factors

Competitor Analysis: PDGF-R Agonists and Antagonists

World Market for Addiction Disorders, 2009-2016

BioPortfolio | Datamonitor Healthcare Reports | Analysis of the Pharmaceutical Market to 2012 - Segmented by Drug Target Family

Analysis of the Pharmaceutical Market to 2012 - Segmented by Drug Target Family

"IntroductionDrug targets are the critical link between drugs and their role in the treatment of medical disorders. By grouping drug targets into key protein families, this report provides a comprehensive analysis of the prescription pharmaceutical market by not just molecule type and therapy area, but also by target family.ScopeClassification of the specific drug targets relating to over 650 key products across the PharmaVitae universe Products grouped into major target families, including GPCRs, enzymes, extracellular signalling proteins (ECS), ion channels and nuclear receptors Comprehensive analysis of forecast sales to 2012 by the three fundamental dimensions of pharma space: molecule type, therapy area and target family Discussion of the factors driving the variable performance of different ATC drug classesHighlightsDatamonitor has identified three fundamental dimensions that describe a product's position within the pharma spacemolecule type, therapy area and target type. Analysis of sales across these dimensions reveals key attractiveness characteristics that drive performance The target type acted on by a product dictates its standing against these key characteristics. Products acting on ECS targets tend to rate most highly and will outperform those acting on other target types. Conversely, products addressing ion channels or nuclear receptors rate poorly and face an overall decline across 200612 The arrival of monoclonal antibody and therapeutic protein technologies allowed ECS targets to be exploited, expanding the 'druggable' target space and driving sales growth across 200612. Beyond 2012, further technological revolutions will, however, be required if the success experienced by these product classes is to be repeatedReasons to PurchaseIdentify product positioning not just in terms of molecule type and therapy area, but also according to target family Rate marketed and pipeline products against the three attractiveness characteristics that determine a product's likelihood of commercial success Understand the challenges faced by different product groups depending on the targets that they address"

23-Oct-07 Format: PDF Pages: 194
Table of Contents
Price: $7,600.00 / €5,084.40

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions